TARDBP and Alzheimer disease: Our findings emphasize the urgent need for the development of in vivo biomarkers specific to limbic-predominant TDP-43 pathology.36 Neuroimaging features, such as fluorodeoxyglucose (FDG)-PET, have been investigated as potential indicators of LATE in vivo.37-39 For example, a temporo-limbic FDG-PET signature has recently been proposed as indicative of LATE.37 Antemortem FDG-PET patterns validated in LATE-NC (N = 7) and AD groups confirmed by autopsy were subsequently applied to stratify an independent cohort with clinically diagnosed AD dementia, identifying cases with LATE-NC–like profiles.